Advances in near infrared photoimmunotherapy of tumor

LI Fang; XIN Junbo; SHI Qin; MAO Chengqiong

doi:10.11665/j.issn.1000-5048.20200604

Journal of China Pharmaceutical University > 2020 > 51(6): 664-674. > DOI: 10.11665/j.issn.1000-5048.20200604

LI Fang, XIN Junbo, SHI Qin, MAO Chengqiong. Advances in near infrared photoimmunotherapy of tumor[J]. Journal of China Pharmaceutical University, 2020, 51(6): 664-674. DOI: 10.11665/j.issn.1000-5048.20200604

Citation:

PDF (27302 KB)

Advances in near infrared photoimmunotherapy of tumor

Funds: This study was supported by the National Natural Science Foundation of China (No.81803452);the Natural Science Foundation of Jiangsu Province (No.BK20180273);

More Information

Received Date: April 19, 2020
Revised Date: September 29, 2020

Graphical Abstract

Abstract

Abstract

Near infrared photoimmunotherapy (NIR-PIT) is a highly selective molecularly targeted phototherapy for cancer which is based on injecting a conjugate of IRDye700DX,a water-soluble near-infrared silicon-phthalocyanine dye,and a monoclonal antibody that targets an antigen on the cancer cell surface. Subsequent local irradiation of NIR light causes the rapid and specific tumor cell death. Due to the good clinical translation prospects of NIR-PIT,this paper summarizes the influencing factors,antitumor mechanism,main challenges and recent strategies,which may benefit for its research and clinical application.
- near infrared photoimmunotherapy,
- tumor,
- targeted photodynamic therapy,
- advances

FullText(HTML)

References (46)

References

[1]	. Nat Med，2011，17（12）：1685?1691.
[2]	Maruoka Y，Furusawa A，Okada R，et al. Combined CD44- and CD25-targeted near-infrared photoimmunotherapy selectively kills cancer and regulatory T cells in syngeneic mouse cancer models［J］. Cancer Immunol Res，2020，8（3）：345?355.
[3]	Sato K，Nagaya T，Mitsunaga M，et al. Near infrared photoimmunotherapy for lung metastases［J］. Cancer Lett，2015，365（1）：112?121.
[4]	Sato K，Nagaya T，Nakamura Y，et al. Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model［J］. Oncotarget，2015，6（23）：19747?19758.
[5]	Kobayashi H，Choyke PL. Near-infrared photoimmunotherapy of cancer［J］. Acc Chem Res，2019，52（8）：2332?2339.
[6]	Zheng L，Tan W，Zhang J，et al. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling［J］. Cancer Immunol Immunother，2014，63（6）：581?586.
[7]	Boeckx C，Blockx L，de Beeck KO，et al. Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines：focus on the contribution of the AP-1 transcription factor［J］. Am J Cancer Res，2015，5（6）：1921?1938.
[8]	Sano K，Nakajima T，Choyke PL，et al. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors［J］. ACS Nano，2013，7（1）：717?724.
[9]	Burley TA，Maczynska J，Shah A，et al. Near-infrared photoimmunotherapy targeting EGFR-shedding new light on glioblastoma treatment［J］. Int J Cancer，2018，142（11）：2363?2374.
[10]	Nishimura T，Mitsunaga M，Sawada R，et al. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody［J］. Cancer Med，2019，8（18）：7781?7792.
[11]	Kiss B，van den Berg NS，Ertsey R，et al. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer［J］. Clin Cancer Res，2019，25（12）：3561?3571.
[12]	Wei W，Jiang D，Ehlerding EB，et al. CD146-targeted multimodal image-guided photoimmunotherapy of melanoma［J］. Adv Sci （Weinh），2019，6（9）：1801237.
[13]	Isobe Y，Sato K，Nishinaga Y，et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer［J］. EBioMedicine，2020，52：102632.
[14]	Sato K，Hanaoka H，Watanabe R，et al. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer［J］. Mol Cancer Ther，2015，14（1）：141?150.
[15]	Nagaya T，Okuyama S，Ogata F，et al. Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination［J］. Gastric Cancer，2019，22（3）：463?472.
[16]	Nagaya T，Okuyama S，Ogata F，et al. Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor （EGFR） antibody［J］. Oncotarget，2018，9（27）：19026?19038.
[17]	Kobayashi H，Griffiths GL，Choyke PL. Near-infrared photoimmunotherapy：photoactivatable antibody-drug conjugates （ADCs）［J］. Bioconjug Chem，2020，31（1）：28?36.
[18]	Li F，Zhao Y，Mao C，et al. RGD-modified albumin nanoconjugates for targeted delivery of a porphyrin photosensitizer［J］. Mol Pharm，2017，14（8）：2793?2804.
[19]	Perez HL，Cardarelli PM，Deshpande S，et al. Antibody-drug conjugates：current status and future directions［J］. Drug Discov Today，2014，19（7）：869?881.
[20]	Amoury M，Bauerschlag D，Zeppernick F，et al. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand［J］. Oncotarget，2016，7（34）：54925?54936.
[21]	Okuyama S，Nagaya T，Sato K，et al. Interstitial near-infrared photoimmunotherapy：effective treatment areas and light doses needed for use with fiber optic diffusers［J］. Oncotarget，2018，9（13）：11159?11169.
[22]	Nakajima T，Sato K，Hanaoka H，et al. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity［J］. BMC Cancer，2014，14：389.
[23]	Sato K，Watanabe R，Hanaoka H，et al. Comparative effectiveness of light emitting diodes （LEDs） and lasers in near infrared photoimmunotherapy［J］. Oncotarget，2016，7（12）：14324?14335.
[24]	Peng W，de Bruijn HS，Farrell E，et al. Epidermal growth factor receptor （EGFR） density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines［J］. Lasers Surg Med，2018，50（5）：513?522.
[25]	Nagaya T，Sato K，Harada T，et al. Near infrared photoimmunotherapy targeting EGFR positive triple negative breast cancer：optimizing the conjugate-light regimen［J］. PLoS One，2015，10（8）：e0136829.
[26]	Kishimoto S，Bernardo M，Saito K，et al. Evaluation of oxygen dependence on in vitro and in vivo cytotoxicity of photoimmunotherapy using IR-700-antibody conjugates［J］. Free Radic Biol Med，2015，85：24?32.
[27]	van Lith SAM，van den Brand D，Wallbrecher R，et al. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates［J］. Eur J Pharm Biopharm，2018，124：63?72.
[28]	Mao C，Zhao Y，Li F，et al. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors［J］. J Control Release，2018，286：289?300.
[29]	Nakamura Y，Nagaya T，Sato K，et al. Alterations of filopodia by near infrared photoimmunotherapy：evaluation with 3D low-coherent quantitative phase microscopy［J］. Biomed Opt Express，2016，7（7）：2738?2748.
[30]	Sano K，Mitsunaga M，Nakajima T，et al. Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET［J］. J Nucl Med，2013，54（5）：770?775.
[31]	Ogata F，Nagaya T，Okuyama S，et al. Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy （3D LC-QPM） after treatment with the near infrared photoimmunotherapy［J］. Oncotarget，2017，8（61）：104295?104302.
[32]	Nakajima K，Takakura H，Shimizu Y，et al. Changes in plasma membrane damage inducing cell death after treatment with near-infrared photoimmunotherapy［J］. Cancer Sci，2018，109（9）：2889?2896.
[33]	Sato K，Watanabe R，Hanaoka H，et al. Photoimmunotherapy：comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor［J］. Mol Oncol，2014，8（3）：620?632.
[34]	Sato K，Choyke PL，Kobayashi H. Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model［J］. PLoS One，2014，9（11）：e113276.
[35]	Kishimoto S，Oshima N，Yamamoto K，et al. Molecular imaging of tumor photoimmunotherapy：evidence of photosensitized tumor necrosis and hemodynamic changes［J］. Free Radic Biol Med，2018，116：1?10.
[36]	Sato K，Ando K，Okuyama S，et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies：a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy［J］. ACS Cent Sci，2018，4（11）：1559?1569.
[37]	Dong H，Wu R，Liu J，et al. Advances in cancer photodynamic therapy［J］. J China Pharm Univ（中国药科大学学报），2016，47（4）：377?387.
[38]	Isoda Y，Piao W，Taguchi E，et al. Development and evaluation of a novel antibody-photon absorber conjugate reveals the possibility of photoimmunotherapy-induced vascular occlusion during treatment in vivo［J］. Oncotarget，2018，9（59）：31422?31431.
[39]	Nagaya T，Okuyama S，Ogata F，et al. Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer［J］. Cancer Sci，2018，109（6）：1902?1908.
[40]	Maruoka Y，Nagaya T，Sato K，et al. Near infrared photoimmunotherapy with combined exposure of external and interstitial light sources［J］. Mol Pharm，2018，15（9）：3634?3641.
[41]	Nakajima K，Kimura T，Takakura H，et al. Implantable wireless powered light emitting diode （LED） for near-infrared photoimmunotherapy：device development and experimental assessment in vitro and in vivo［J］. Oncotarget，2018，9（28）：20048?20057.
[42]	Mitsunaga M，Nakajima T，Sano K，et al. Near-infrared theranostic photoimmunotherapy （PIT）：repeated exposure of light enhances the effect of immunoconjugate［J］. Bioconjug Chem，2012，23（3）：604?609.
[43]	Mitsunaga M，Nakajima T，Sano K，et al. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy［J］. BMC Cancer，2012，12：345.
[44]	Okuyama S，Nagaya T，Ogata F，et al. Avoiding thermal injury during near-infrared photoimmunotherapy （NIR-PIT）：the importance of NIR light power density［J］. Oncotarget，2017，8（68）：113194?113201.
[45]	Nakajima T，Sano K，Mitsunaga M，et al. Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging［J］. Cancer Res，2012，72（18）：4622?4628.
[46]	Maruoka Y，Nagaya T，Nakamura Y，et al. Evaluation of early therapeutic effects after near-infrared photoimmunotherapy （NIR-PIT） using luciferase-luciferin photon-counting and fluorescence imaging［J］. Mol Pharm，2017，14（12）：4628?4635.

[1]	LI Yin, GU Hongfeng, ZOU Yi, WANG Shuping, XU Yungen. Research progress of mono-(ADP-ribosyl) transferase family and their inhibitors in tumor therapy[J]. Journal of China Pharmaceutical University, 2021, 52(6): 643-652. DOI: 10.11665/j.issn.1000-5048.20210601
[2]	SUN Chenkai, CHEN Xin, CHENG Hao, ZHANG Xiangze, YANG Xiaoyu, ZHOU Jianping, DING Yang. Advances of research on oxygen-enhancing nano-delivery system for photodynamic therapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 387-397. DOI: 10.11665/j.issn.1000-5048.20210401
[3]	FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
[4]	TANG Keqin, LIN Huaqing, LI Shuhong, DONG Lixin, LU Bohong, JIANG Hong. Advances in tumor targeted nanocrystals[J]. Journal of China Pharmaceutical University, 2020, 51(4): 418-424. DOI: 10.11665/j.issn.1000-5048.20200405
[5]	CHEN Ye, YIN Jun, YAO Wenbing, GAO Xiangdong. Advances of DNA-based nanomaterials in tumor therapy[J]. Journal of China Pharmaceutical University, 2020, 51(4): 406-417. DOI: 10.11665/j.issn.1000-5048.20200404
[6]	XU Xiangting, WANG Wei. Advances of functionalized carbon nanotubes in diagnosis and treatment of tumor[J]. Journal of China Pharmaceutical University, 2018, 49(2): 165-172. DOI: 10.11665/j.issn.1000-5048.20180205
[7]	CAI Han, LIU Yanhong, YIN Tingjie, ZHOU Jianping, HUO Meirong. Advances in the targeted therapy of tumor-associated fibroblasts[J]. Journal of China Pharmaceutical University, 2018, 49(1): 20-25. DOI: 10.11665/j.issn.1000-5048.20180103
[8]	WANG Letian, WANG Jinglin, LIU Hongwu, GE Ying, LI Yuyan, XU Qingxiang. Process in targeted contrast agents for cancer imaging[J]. Journal of China Pharmaceutical University, 2017, 48(6): 635-645. DOI: 10.11665/j.issn.1000-5048.20170602
[9]	DONG Hong, WU Ruixue, LIU Jiaqi, HUANG Qing, ZHOU Ya, HU Yiqiao. Advances in cancer photodynamic therapy[J]. Journal of China Pharmaceutical University, 2016, 47(4): 377-387. DOI: 10.11665/j.issn.1000-5048.20160401
[10]	HUANG Shaoliang, ZHAO Li, GUO Qinglong, WU Yulin. Advances of Hedgehog pathway in tumor resistance[J]. Journal of China Pharmaceutical University, 2016, 47(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20160302

Cited By

Cited by

Periodical cited type(2)

1.	施薏，冯镜闻. 近红外光免疫治疗策略靶向肿瘤微环境的研究进展. 中国处方药. 2025(01): 104-107 .
2.	徐欣瑶，赵丽娜，卢佳煜，张旭旭，郑春龙，李家贺，李玮，卢强. 食管癌中肿瘤相关成纤维细胞的异质性及靶向治疗. 重庆医科大学学报. 2024(12): 1550-1555 .

Other cited types(1)

Get Citation

PDF

XML

Article views (426) PDF downloads (1020) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Advances in near infrared photoimmunotherapy of tumor

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Advances in near infrared photoimmunotherapy of tumor

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Export File

Citation

Format

Content